What Clinical Trials Are and Why They Matter

Clinical trials are research studies that test new medical treatments, drugs, devices, or procedures on human participants. These studies help determine whether a new medical approach is safe and whether it works better than current standard treatments. Before any medication or medical device reaches patients in hospitals or pharmacies, it typically goes through years of testing in clinical trials.

Get Your Free Florida Real Estate License Guide →

The process of bringing a new drug to market can take 10 to 15 years and cost billions of dollars. During this time, researchers conduct different phases of trials to gather evidence about safety and effectiveness. Without clinical trials, doctors would have no way to know if a new treatment actually helps patients or if it causes harmful side effects.

Clinical trials occur in different settings—medical centers, hospitals, research institutions, and private practices. Some trials involve testing a new cancer drug, while others might study a new surgical technique or a device like a pacemaker. Each trial has specific goals, which means not all trials test medicines. Some explore how to prevent diseases, while others focus on improving quality of life for people with existing conditions.

The people who participate in clinical trials play a critical role in medical advancement. Their participation provides the real-world evidence that helps answer questions about whether new treatments work. However, participating in a trial means following strict guidelines and having regular medical visits, lab tests, and monitoring.

Practical Takeaway: Understanding what clinical trials are helps you learn how new medical treatments are developed and tested. Clinical trials are necessary research studies that ultimately protect patients by ensuring new treatments are safe and effective before they become widely available.

The Phases of Clinical Trial Development

Clinical trials follow a structured process called phases, and each phase serves a different purpose. The phases are numbered 1 through 4, and sometimes there are additional phases. Understanding these phases helps you see why trials take so long and why they involve so many participants.

Learn About Coursera Certificate Costs and Options →

Phase 1 trials are the earliest stage where a new treatment is tested in humans for the first time. These trials typically involve 20 to 100 healthy volunteers (though sometimes people with the disease being studied participate). The main goal is to determine safety and find the right dose. Researchers watch carefully for side effects and may increase the dose gradually to find the highest dose that is safe. Phase 1 can last several months.

Phase 2 trials involve 100 to 500 people who have the disease or condition being studied. These trials continue to monitor safety while also beginning to look at whether the treatment actually works. Phase 2 trials usually take several months to two years. Researchers continue to study different doses and watch for side effects. Not all treatments move forward from Phase 2—some are found to be ineffective or cause too many side effects.

Phase 3 trials are larger studies that typically involve 1,000 to 5,000 participants who have the disease. At this stage, researchers compare the new treatment to the current standard treatment or a placebo (a fake treatment). They measure how well the new treatment works and monitor side effects in a larger population. Phase 3 trials usually last from one to four years. This phase generates most of the evidence that doctors will use to decide whether to use the new treatment.

Phase 4 trials happen after a treatment has been approved and is already available to patients. These studies continue to monitor safety and effectiveness in the general population over many years. Phase 4 helps researchers find rare side effects that might not appear in earlier trials or discover new uses for the treatment.

Practical Takeaway: Each phase of clinical trials has a specific purpose and involves different numbers of participants. Understanding the phases helps you see why clinical trials take years—researchers must gather safety and effectiveness information at each stage before moving forward.

How the FDA Reviews and Approves Clinical Trials

The Food and Drug Administration (FDA) is the government agency responsible for reviewing clinical trials and deciding whether new medical treatments can be tested on humans and, eventually, whether they can be sold to the public. The FDA has strict rules about how trials must be conducted to protect people who participate.

Learn How to Change Your Homepage in Chrome Firefox and Edge →

Before a clinical trial can begin, researchers must submit an Investigational New Drug (IND) application to the FDA. This application includes all the research done so far, information about the drug's safety from laboratory and animal studies, details about how the trial will be conducted, and information about the researchers conducting the trial. The FDA has 30 days to review an IND application. If the FDA has concerns about safety or the trial's design, it can request more information or place the trial on hold.

Throughout the trial, the FDA continues to monitor progress. Researchers must report serious side effects to the FDA immediately. The FDA also requires that each trial have an Institutional Review Board (IRB), which is a group of doctors, scientists, and community members who review the trial at the research site. The IRB ensures that the trial is conducted ethically and that participants' rights are protected.

After Phase 3 trials are completed, researchers submit a New Drug Application (NDA) or Biologics License Application (BLA) to the FDA. This massive document can contain hundreds of thousands of pages describing everything learned about the drug—how it works, safety data, effectiveness data, and how it should be manufactured and labeled. The FDA reviews this application carefully, usually taking several months to more than a year. FDA reviewers may request additional information or studies before making a decision.

The FDA can approve the new treatment, request more information, or reject it. If approved, the treatment receives a label that describes what disease it treats, how to use it, and what side effects might occur. This label must be based on the evidence from clinical trials.

Practical Takeaway: The FDA oversees clinical trials to ensure they are safe and that the evidence supporting new treatments is solid. Multiple layers of review—including the FDA, Institutional Review Boards, and researchers—work together to protect trial participants and ensure that only effective and safe treatments reach patients.

Institutional Review Boards and Participant Protection

An Institutional Review Board (IRB) is a group of people responsible for reviewing clinical trials before they begin and monitoring them throughout the study. The IRB's main job is to protect the rights, safety, and welfare of people who participate in research. Every clinical trial must have IRB approval before any participants can be enrolled.

Your Free Guide to Teaching Parrots to Speak →

IRBs typically have at least five members, and they must include a mix of people from different backgrounds. A typical IRB includes physicians and scientists who understand the medical field being studied, a community member with no medical background, a member who represents the legal and ethical side of research, and sometimes a person from the local community. This mix ensures that trials are reviewed from multiple perspectives.

The IRB reviews the trial protocol, which is a detailed plan describing what will be tested, how many people will participate, what procedures participants will undergo, what risks exist, and what benefits might result. The IRB also reviews the informed consent form, which is the document that participants read to learn about the trial. The IRB checks that the information is written in language that people can understand and that all risks are clearly explained.

The IRB evaluates whether the risks of the trial are reasonable compared to the potential benefits. Sometimes an IRB will approve a trial with significant risks if the potential benefit is large enough, such as a trial for a life-threatening disease where no good treatment exists. However, if the IRB believes a trial is too risky or the informed consent form is not clear enough, it can deny approval or require changes before approval.

After a trial begins, the IRB continues to monitor it. Researchers must report any serious side effects or unexpected events to the IRB. The IRB conducts regular reviews, usually at least once per year, to ensure the trial is still being conducted safely and ethically. If safety problems emerge, the IRB can stop the trial.

Practical Takeaway: Institutional Review Boards are an important safeguard that protects people in clinical trials. Understanding that IRBs exist and regularly monitor trials can help you understand that multiple layers of oversight protect trial participants beyond just FDA review.

Informed Consent and Participant Rights

Informed consent is a process, not just a document. It means that before someone participates in a clinical trial, they receive complete information about the trial and have the opportunity to ask questions and make a free choice about whether to participate. Informed consent is a legal and ethical requirement for all clinical trials.

Learn About Activities at Clovis Senior Center →

The informed consent form